Sodium selenite inhibits cervical cancer growth via ROS mediated AMPK/FOXO3a /GADD45a axis.


Journal

Chemico-biological interactions
ISSN: 1872-7786
Titre abrégé: Chem Biol Interact
Pays: Ireland
ID NLM: 0227276

Informations de publication

Date de publication:
01 Nov 2022
Historique:
received: 24 06 2022
revised: 26 08 2022
accepted: 04 09 2022
pubmed: 16 9 2022
medline: 13 10 2022
entrez: 15 9 2022
Statut: ppublish

Résumé

Selenium is a trace element that has been shown to inhibit the growth of various cancer cell types. However, its role in cervical cancer and its underlying mechanisms remains largely unknown. Herein, we explored the anti-cervical cancer effect of selenium and its potential mechanisms through xenograft and in vitro experiments. HeLa cell xenografts in female nude mice showed tumor growth retardation, with no obvious liver and kidney toxicity, after being intraperitoneally injected with 3 mg/kg sodium selenite (SS) for 14 days. Compared to the control group, selenium levels in the tumor tissue increased significantly after SS treatment. In vitro experiments, SS inhibited the viability of HeLa and SiHa cells, blocked the cell cycle at the S phase, and enhanced apoptosis. RNA-sequencing, Kyoto encyclopedia of genes and genomes pathway analysis showed that forkhead box protein O (FOXO) was a key regulatory signaling pathway for SS to exhibit anticancer effects. Gene Ontology analysis filtered multiple terms associated with apoptosis, anti-proliferation, and cell cycle arrest. Further research revealed that SS increased intracellular reactive oxygen species (ROS) and impaired mitochondrial function, which activated adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) via phosphorylation at Thr172, resulting in activation of FOXO3a and its downstream growth arrest and DNA damage-inducible alpha (GADD45a). In summary, SS exhibited anti-cervical cancer effects, and their mechanisms may be that SS is involved in inducing cell cycle arrest and potentiating cell apoptosis caused by ROS-dependent activation of the AMPK/FOXO3a/GADD45a axis.

Identifiants

pubmed: 36108716
pii: S0009-2797(22)00376-3
doi: 10.1016/j.cbi.2022.110171
pii:
doi:

Substances chimiques

Cell Cycle Proteins 0
Forkhead Box Protein O3 0
Forkhead Transcription Factors 0
GADD45A protein, human 0
Reactive Oxygen Species 0
Trace Elements 0
Adenosine Monophosphate 415SHH325A
RNA 63231-63-0
AMP-Activated Protein Kinases EC 2.7.11.31
Selenium H6241UJ22B
Sodium Selenite HIW548RQ3W
Adenosine K72T3FS567

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110171

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lei Qi (L)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Yuanyuan Wang (Y)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Shengqi Su (S)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Mingxing Wang (M)

Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, 150081, China.

Ewa Jablonska (E)

Department of Translational Research, Nofer Institute of Occupational Medicine, Sw. Teresy 8 Street, Lodz, 91-348, Poland.

Yuehui Jia (Y)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Ruixiang Wang (R)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Shuxiu Hao (S)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Chen Feng (C)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Guijin Li (G)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Meijing Jiang (M)

Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, 150081, China.

Linlin Du (L)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Huixin Sun (H)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China.

Qi Li (Q)

Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, 150081, China. Electronic address: liqi@ems.hrbmu.edu.cn.

Tong Wang (T)

Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin, 150081, China. Electronic address: wangtong@ems.hrbmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH